Background: To determine practice patterns and outcomes of laryngeal small cell cancer (LSCC) across the United States. Methods: Patients with LSCC were identified in the National Cancer Database. Overall survival (OS) was compared with Kaplan-Meier analysis and Cox regression. Results: From 2004 to 2014, the 5-year OS for early stage (n = 47), locally advanced stage (n = 133), and metastatic disease (n = 53) was 34%, 26%, and 9%, respectively. Chemoradiation was given in 66% of cases. Chemotherapy was less likely given in early stage disease (P =.001), and definitive radiation was less likely given in metastatic disease (P <.001). Definitive radiation improved median OS in locally advanced LSCC (20 vs. 7 months, log-rank P =.04). In multivariable modeling, radiation dose ≥40 Gy was associated with better OS (P <.001). Conclusion: Chemoradiation was the most common practice for treating locally advanced LSCC, and radiation dose ≥40 Gy was associated with improved OS.
- head and neck
- neuroendocrine cancer